SEC 13F Intelligence

Duquesne Family Office LLC / CRNX

Duquesne Family Office LLC’s Crinetics Pharmaceuticals In Position

Does Duquesne Family Office LLC own Crinetics Pharmaceuticals In (CRNX)? Not currently — the last reported position was 122.7K shares worth $6M in Q4 2024; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$6M
Q4 2024
Shares
122.7K
% of Portfolio
+0.17%
Quarters Held
4
position exited

Position History CRNX

Reported value by quarter
Q1 ’24: $14MQ1 ’24Q2 ’24: $14MQ2 ’24Q3 ’24: $16MQ3 ’24Q4 ’24: $6MQ4 ’24filingsflow.com
QuarterSharesValue% of Portfolio
Q4 2024122.7K$6M+0.17%
Q3 2024309.0K$16M+0.53%
Q2 2024309.0K$14M+0.47%
Q1 2024309.0K$14M+0.33%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Duquesne Family Office LLC’s full portfolio or all institutional holders of CRNX.